Glucose Sensor After Hospital Discharge for People With Type 2 or Steroid-Induced Diabetes
Tests a wearable glucose sensor in adults with diabetes going home on insulin.
Plain-language title generated from the registry record
Registry title: CGM After Discharge From Hospital
Key facts
- Where
- New York, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 or steroid-induced diabetes who were treated in hospital and will use insulin after discharge. It compares two ways of monitoring blood sugar.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes or steroid-induced diabetes, treated in hospital, with a plan for insulin use after discharge
- Earlier treatment
- Inpatient treatment for type 2 or steroid-induced diabetes during the hospital stay
Main reasons for not taking part
- Type 1 diabetes
- Plan to be discharged to a rehabilitation, skilled nursing or hospice facility
- Contra-indication to sensor placement
- Pregnancy
Read by machine on 9 November 2026.
Where in United States
- Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Trial code
- NCT07510386
- Record updated
- 10 August 2026
- Original description
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.Read full original descriptionShow less
Continuous Glucose Monitoring for Post-discharge Diabetes Management
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.
Inclusion: Adult 18 years or older; Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge.
Exclusion: Type 1 diabetes; Plan for discharge to rehabilitation/skilled nursing/hospice facility; Contra-indication to sensor placement; Pregnancy.